Axon Enterprise (NASDAQ:AXON) Stock Price Up 8.9% – Should You Buy?

Axon Enterprise, Inc (NASDAQ:AXON) shares rose 8.9% on Monday . The company traded as high as $505.55 and last traded at $506.3640. Approximately 188,186 shares traded hands during trading, a decline of 83% from the average daily volume of 1,084,276 shares. The stock had previously closed at $464.83.

Key Headlines Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Investor enthusiasm is being fueled by reports that President Trump bought Axon shares before ICE posted a notice for a possible $220 million Taser contract, which traders see as a potential demand catalyst for Axon’s law-enforcement technology. Trump bought as much as $5 million in Axon stock before ICE sought $220 million Taser deal
• Positive Sentiment: Axon’s underlying business momentum is also supporting the stock, with Q1 revenue up 34% year over year and management raising its 2026 growth outlook. Axon Enterprise jumps as investors react to disclosure-linked contract narrative and strong operating momentum
• Neutral Sentiment: Analysts remain broadly constructive, with Northland Securities reaffirming a buy rating and several recent price targets still above current trading levels. Northland Securities Reaffirms Their Buy Rating on Axon Enterprise (AXON)
• Neutral Sentiment: Recent commentary also highlights that the stock’s run-up may be driven as much by headline momentum and political news as by fundamentals alone. Axon Enterprise (AXON) Stock After Recent Volatility Is The Current Price Justified
• Negative Sentiment: The Trump-Axon-ICE narrative has sparked conflict-of-interest and ethics concerns, which could create political and reputational risk around future government contracting. Axon Enterprise (AXON) Stock Drew Ethics Questions After Trump Bought $5 Million In Shares
• Negative Sentiment: Sentiment is also pressured by ongoing insider selling, including CEO Patrick Smith’s recent sale of 10,000 shares under a pre-arranged trading plan. SEC filing for Patrick Smith Axon sale

Analyst Upgrades and Downgrades

Several analysts recently issued reports on AXON shares. Zacks Research raised shares of Axon Enterprise from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 19th. JPMorgan Chase & Co. boosted their target price on Axon Enterprise from $750.00 to $755.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Citizens Jmp restated a “market outperform” rating and issued a $700.00 price target on shares of Axon Enterprise in a research report on Thursday, June 25th. Morgan Stanley set a $600.00 price target on Axon Enterprise in a research report on Thursday, May 7th. Finally, UBS Group reduced their price objective on Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating on the stock in a research report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Axon Enterprise has a consensus rating of “Moderate Buy” and a consensus price target of $712.75.

Axon Enterprise Trading Up 9.8%

The company has a quick ratio of 1.93, a current ratio of 2.27 and a debt-to-equity ratio of 0.49. The company’s 50-day moving average is $426.15 and its 200-day moving average is $481.27. The stock has a market capitalization of $45.19 billion, a price-to-earnings ratio of 225.14, a PEG ratio of 10.42 and a beta of 1.45.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.01. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The company had revenue of $807.35 million for the quarter, compared to analyst estimates of $778.90 million. During the same period in the previous year, the business posted $1.47 EPS. Axon Enterprise’s revenue was up 33.7% on a year-over-year basis. Research analysts anticipate that Axon Enterprise, Inc will post 1.63 earnings per share for the current fiscal year.

Insider Activity

In other Axon Enterprise news, President Joshua Isner sold 13,000 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $488.45, for a total transaction of $6,349,850.00. Following the completion of the sale, the president owned 169,125 shares of the company’s stock, valued at $82,609,106.25. This trade represents a 7.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Caitlin Elizabeth Kalinowski sold 564 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $478.97, for a total value of $270,139.08. Following the sale, the director directly owned 3,632 shares of the company’s stock, valued at approximately $1,739,619.04. This trade represents a 13.44% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 48,989 shares of company stock worth $24,090,083. 4.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Axon Enterprise

A number of hedge funds have recently modified their holdings of the business. Rockefeller Capital Management L.P. boosted its stake in Axon Enterprise by 53.2% during the 4th quarter. Rockefeller Capital Management L.P. now owns 11,518 shares of the biotechnology company’s stock worth $6,542,000 after purchasing an additional 4,002 shares during the period. Legal & General Group Plc raised its holdings in shares of Axon Enterprise by 1.3% in the fourth quarter. Legal & General Group Plc now owns 426,533 shares of the biotechnology company’s stock valued at $242,241,000 after buying an additional 5,419 shares during the last quarter. Eurizon Capital SGR S.p.A. purchased a new stake in shares of Axon Enterprise in the fourth quarter valued at about $13,116,000. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Axon Enterprise by 93.1% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 23,365 shares of the biotechnology company’s stock worth $13,270,000 after buying an additional 11,262 shares during the period. Finally, Teamwork Financial Advisors LLC boosted its stake in shares of Axon Enterprise by 40.5% during the fourth quarter. Teamwork Financial Advisors LLC now owns 25,352 shares of the biotechnology company’s stock worth $14,398,000 after buying an additional 7,307 shares during the period. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.